Atlas Trials

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Clinical trial NCT07383298 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT07383298
Sponsor
Qian Jiang
Status
ENROLLING_BY_INVITATION
Study type
OBSERVATIONAL
Chronic Myeloid Leukemia
Start date
2025-12-16
Primary completion
2028-12-31
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.